Stelara (Ustekinumab) Industry Report 2025-2034: Market Dynamics, Drivers, And Forecasts

The Stelara (Ustekinumab) Market Report by The Business Research Company delivers a detailed market assessment, covering size projections from 2025 to 2034. This report explores crucial market trends, major drivers and market segmentation by [key segment categories].

What Is the Expected Stelara (Ustekinumab) Market Size During the Forecast Period?
Over the past few years, there has been robust growth in the market size of Stelara (ustekinumab). It is projected to increase from $11,177.34 million in 2024 to $11,850.79 million in 2025, with a compound annual growth rate (CAGR) of 6.0%. This growth in the historical period can be credited to an increase in healthcare expenditure, the expansion of specialty drug distribution networks, enlarging clinical trial programs, investing in research and development, and the growing use of telemedicine which eases access to treatment.

Expectations are high for the strong growth of the Stelara (ustekinumab) market in the coming years. By 2029, it is projected to reach $14,768.48 million, with a compound annual growth rate (CAGR) of 5.7%. This growth in the forecast period is driven by the widening of Stelara's use, the rising incidence of autoimmune diseases, its high efficacy in resistant cases in comparison to other alternatives, increasing consciousness of patients and medical providers, and reinforced emphasis on personalized medicine. Looking ahead, principal trends for the forecast period are the acceptance of biologic therapies, advancements in drug delivery systems, data-informed healthcare systems, collaboration and licensing agreements among pharmaceutical companies, and innovations in biologics production technologies.

Purchase the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19935

What Are the High-Growth Segments in the Stelara (Ustekinumab) Market?
The stelara (ustekinumab) market covered in this report is segmented -

1) By Indication: Plaque Psoriasis; Psoriatic Arthritis; Crohn's Disease; Ulcerative Colitis; Other Indications
2) By Route Of Administration: Subcutaneous Injection; Intravenous Infusion
3) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
4) By End User: Pediatric; Adult; Geriatric

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=19935&type=smp

What Key Drivers Are Expected to Influence Future Stelara (Ustekinumab) Market Growth?
The growth of the stelara (ustekinumab) market is anticipated to be driven forward due to the increasing prevalence of psoriasis patients. These patients suffer from a chronic autoimmune disorder that speeds up skin cell turnover, leading to the formation of red, scaly patches. The increasing presence of these patients can be associated with several factors, such as enhanced diagnosis techniques, environmental instigators, genetic possibilities, and an elderly population. By targeting and inhibiting interleukin-12 and interleukin-23, Stelara (ustekinumab) aids psoriasis patients by effectively minimizing inflammation and plaque formation. This results in better skin clearance and long-term symptom control, thereby improving their quality of life. In May 2024, for instance, a report by the National Library of Medicine, an American medical library, stated that the prevalence of psoriasis rose to 0.221% in 2022, with 6,930 PsA cases reported amongst a population of 3,133,500. Consequently, these factors are likely to facilitate the anticipated growth of the stelara (ustekinumab) market influenced by the rising prevalence of psoriasis patients.

Which Companies Hold the Largest Share Across Different Stelara (Ustekinumab) Market Segments?
Major companies operating in the stelara (ustekinumab) market include Johnson & Johnson

What Admelog Market Trends Are Gaining Traction Across Different Segments?
A significant trend in the Stelara (Ustekinumab) market is the development of groundbreaking products like Stelara biosimilars, offering cost-efficient treatment choices for individuals suffering from chronic inflammatory disorders. These biosimilars are designed to mimic the therapeutic benefits of Stelara (Ustekinumab), specifically targeting IL-12 and IL-23 for the treatment of autoimmune disorders such as psoriasis and psoriatic arthritis. For example, in October 2024, the American biopharmaceutical company, Accord BioPharma Inc., received approval from the U.S. Food and Drug Administration (FDA) for their product IMULDOSA (ustekinumab-srlf), a biosimilar to Johnson & Johnson's STELARA (ustekinumab). The versatility of IMULDOSA is remarkable, providing treatment for adults suffering from moderate to severe plaque psoriasis, active psoriatic arthritis, moderately to severely active Crohn's disease, and ulcerative colitis. Additionally, it's suitable for kids aged 6 and above with moderate to severe plaque psoriasis and active psoriatic arthritis, making it adaptable across different age groups. This extensive range of applications establishes IMULDOSA as a beneficial choice for treating various immune-mediated inflammatory conditions.

Get the full report for exclusive industry analysis:
https://www.thebusinessresearchcompany.com/report/stelara-ustekinumab-global-market-report-

What Are the Emerging Geographies for The Stelara (Ustekinumab) Market Growth?
North America was the largest region in the stelara (ustekinumab) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the stelara (ustekinumab) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Frequently Asked Questions:
1. What Is the Market Size and Growth Rate of the Stelara (Ustekinumab) Market?
2. What is the CAGR expected in the Stelara (Ustekinumab) Market?
3. What Are the Key Innovations Transforming the Stelara (Ustekinumab) Industry?
4. Which Region Is Leading the Stelara (Ustekinumab) Market?

Why This Report Matters:

Competitive overview: This report analyzes the competitive landscape of the 3D imaging software market, evaluating key players on market share, revenue, and growth factors.

Informed Decisions: Understand key strategies related to products, segmentation, and industry trends.

Efficient Research: Quickly identify market growth, leading players, and major segments.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.